We observed both trait- or risk-increasing and -decreasing associations upon the genes’ assumed loss of function (Fig. 4b), highlighting opportunities in which therapeutic target inhibition confers protection as exemplified by ANGPTL3 and dyslipidemia, for which new drugs have recently gained approval23. The gene discussed is ANGPTL3; the disease is metabolic syndrome.